vs

Side-by-side financial comparison of CHIMERA INVESTMENT CORP (CIM) and Core Laboratories Inc. (CLB). Click either name above to swap in a different company.

Core Laboratories Inc. is the larger business by last-quarter revenue ($121.8M vs $66.2M, roughly 1.8× CHIMERA INVESTMENT CORP). CHIMERA INVESTMENT CORP runs the higher net margin — 42.8% vs 4.2%, a 38.6% gap on every dollar of revenue. On growth, CHIMERA INVESTMENT CORP posted the faster year-over-year revenue change (0.5% vs -1.4%). Over the past eight quarters, CHIMERA INVESTMENT CORP's revenue compounded faster (0.8% CAGR vs -3.4%).

Chimera Investment Corp is a US-based real estate investment trust (REIT) primarily investing in residential mortgage-backed securities, residential and commercial mortgage loans, and other real estate-related financial assets. It delivers sustainable risk-adjusted returns for shareholders via regular dividend distributions from its investment portfolio.

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.

CIM vs CLB — Head-to-Head

Bigger by revenue
CLB
CLB
1.8× larger
CLB
$121.8M
$66.2M
CIM
Growing faster (revenue YoY)
CIM
CIM
+2.0% gap
CIM
0.5%
-1.4%
CLB
Higher net margin
CIM
CIM
38.6% more per $
CIM
42.8%
4.2%
CLB
Faster 2-yr revenue CAGR
CIM
CIM
Annualised
CIM
0.8%
-3.4%
CLB

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CIM
CIM
CLB
CLB
Revenue
$66.2M
$121.8M
Net Profit
$28.3M
$5.1M
Gross Margin
Operating Margin
42.6%
1.5%
Net Margin
42.8%
4.2%
Revenue YoY
0.5%
-1.4%
Net Profit YoY
119.3%
EPS (diluted)
$0.05
$0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CIM
CIM
CLB
CLB
Q1 26
$121.8M
Q4 25
$66.2M
$138.3M
Q3 25
$65.0M
$134.5M
Q2 25
$66.0M
$130.2M
Q1 25
$69.2M
$123.6M
Q4 24
$65.8M
$129.2M
Q3 24
$66.5M
$134.4M
Q2 24
$67.3M
$130.6M
Net Profit
CIM
CIM
CLB
CLB
Q1 26
$5.1M
Q4 25
$28.3M
$4.9M
Q3 25
$-580.0K
$14.2M
Q2 25
$35.5M
$10.6M
Q1 25
$167.3M
$-154.0K
Q4 24
$-146.5M
$7.4M
Q3 24
$136.5M
$11.7M
Q2 24
$56.7M
$9.0M
Gross Margin
CIM
CIM
CLB
CLB
Q1 26
Q4 25
20.8%
Q3 25
22.0%
Q2 25
20.3%
Q1 25
19.5%
Q4 24
17.8%
Q3 24
20.5%
Q2 24
21.2%
Operating Margin
CIM
CIM
CLB
CLB
Q1 26
1.5%
Q4 25
42.6%
11.5%
Q3 25
-0.5%
15.6%
Q2 25
54.3%
11.7%
Q1 25
3.6%
Q4 24
-222.6%
11.0%
Q3 24
14.7%
Q2 24
84.2%
12.3%
Net Margin
CIM
CIM
CLB
CLB
Q1 26
4.2%
Q4 25
42.8%
3.6%
Q3 25
-0.9%
10.6%
Q2 25
53.7%
8.2%
Q1 25
241.7%
-0.1%
Q4 24
-222.6%
5.7%
Q3 24
205.4%
8.7%
Q2 24
84.2%
6.9%
EPS (diluted)
CIM
CIM
CLB
CLB
Q1 26
$0.11
Q4 25
$0.05
$0.11
Q3 25
$-0.27
$0.30
Q2 25
$0.17
$0.22
Q1 25
$1.77
$0.00
Q4 24
$-2.06
$0.15
Q3 24
$1.39
$0.25
Q2 24
$0.41
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CIM
CIM
CLB
CLB
Cash + ST InvestmentsLiquidity on hand
$278.6M
$22.8M
Total DebtLower is stronger
$251.5M
Stockholders' EquityBook value
$2.6B
$275.1M
Total Assets
$15.8B
$587.7M
Debt / EquityLower = less leverage
0.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CIM
CIM
CLB
CLB
Q1 26
$22.8M
Q4 25
$278.6M
$22.7M
Q3 25
$491.5M
$25.6M
Q2 25
$250.2M
$31.2M
Q1 25
$253.3M
$22.1M
Q4 24
$84.0M
$19.2M
Q3 24
$97.3M
$21.5M
Q2 24
$162.3M
$17.7M
Total Debt
CIM
CIM
CLB
CLB
Q1 26
Q4 25
$251.5M
$110.3M
Q3 25
$251.0M
$114.1M
Q2 25
$135.2M
$124.6M
Q1 25
$134.9M
$124.4M
Q4 24
$134.6M
$126.1M
Q3 24
$134.4M
$139.9M
Q2 24
$62.4M
$147.6M
Stockholders' Equity
CIM
CIM
CLB
CLB
Q1 26
$275.1M
Q4 25
$2.6B
$266.0M
Q3 25
$2.6B
$271.3M
Q2 25
$2.6B
$261.3M
Q1 25
$2.6B
$253.4M
Q4 24
$2.5B
$246.6M
Q3 24
$2.7B
$250.7M
Q2 24
$2.6B
$240.3M
Total Assets
CIM
CIM
CLB
CLB
Q1 26
$587.7M
Q4 25
$15.8B
$584.0M
Q3 25
$15.1B
$591.4M
Q2 25
$14.9B
$602.1M
Q1 25
$13.2B
$591.5M
Q4 24
$13.1B
$585.1M
Q3 24
$13.7B
$600.5M
Q2 24
$13.1B
$597.8M
Debt / Equity
CIM
CIM
CLB
CLB
Q1 26
Q4 25
0.10×
0.41×
Q3 25
0.10×
0.42×
Q2 25
0.05×
0.48×
Q1 25
0.05×
0.49×
Q4 24
0.05×
0.51×
Q3 24
0.05×
0.56×
Q2 24
0.02×
0.61×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CIM
CIM
CLB
CLB
Operating Cash FlowLast quarter
$-248.9M
$4.0M
Free Cash FlowOCF − Capex
$517.0K
FCF MarginFCF / Revenue
0.4%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
-8.78×
0.77×
TTM Free Cash FlowTrailing 4 quarters
$22.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CIM
CIM
CLB
CLB
Q1 26
$4.0M
Q4 25
$-248.9M
$7.9M
Q3 25
$-137.5M
$8.5M
Q2 25
$-7.4M
$13.9M
Q1 25
$48.8M
$6.7M
Q4 24
$205.7M
$20.6M
Q3 24
$41.4M
$13.1M
Q2 24
$69.0M
$17.1M
Free Cash Flow
CIM
CIM
CLB
CLB
Q1 26
$517.0K
Q4 25
$5.0M
Q3 25
$6.5M
Q2 25
$10.4M
Q1 25
$3.9M
Q4 24
$17.4M
Q3 24
$10.4M
Q2 24
$14.3M
FCF Margin
CIM
CIM
CLB
CLB
Q1 26
0.4%
Q4 25
3.6%
Q3 25
4.8%
Q2 25
8.0%
Q1 25
3.1%
Q4 24
13.4%
Q3 24
7.7%
Q2 24
10.9%
Capex Intensity
CIM
CIM
CLB
CLB
Q1 26
Q4 25
2.1%
Q3 25
1.5%
Q2 25
2.7%
Q1 25
2.3%
Q4 24
2.5%
Q3 24
2.0%
Q2 24
2.2%
Cash Conversion
CIM
CIM
CLB
CLB
Q1 26
0.77×
Q4 25
-8.78×
1.61×
Q3 25
0.60×
Q2 25
-0.21×
1.31×
Q1 25
0.29×
Q4 24
2.78×
Q3 24
0.30×
1.12×
Q2 24
1.22×
1.90×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons